anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
With the recent emergence of percutaneous balloon compression (PBC) as a promising treatment for trigeminal neuralgia (TN), there is a growing need for research on its safety and efficacy. This study was designed to evaluate the safety and efficacy of PBC in the treatment of TN patients during the perioperative period. This study involved a total of 400 TN patients who were selected and treated with PBC at our institution. The clinical data and short-term outcomes were analyzed based on sex, initial PBC treatment for TN, and subsequent PBC treatment for recurrent TN after previous PBC or microvascular decompression (MVD) or radiofrequency thermocoagulation (RFT). No statistically significant difference was found when comparing postoperative pain relief between male and female patients with TN. Nevertheless, female patients were found to be more vulnerable than male patients to abnormal facial sensations (P = 0.001), diplopia (P = 0.015), postoperative headache (P = 0.012), and hyposmia (P = 0.029). Additionally, it was observed that there was no substantial difference in the postoperative pain relief rate between the first-time PBC group and PBC for recurrent TN patients postoperatively following procedures such as PBC, MVD, and RFT. In conclusion, this study has shown that PBC treatment is effective in managing TN in both males and females, regardless of whether the treatment was administered as a primary intervention or following prior surgical procedures such as PBC, MVD, or RFT. Nonetheless, it is noted that the risk of postoperative complications appears to be higher in female patients compared to male patients.
It is stated that the university period is risky in terms of acquiring negative health behaviors that may cause overweight and obesity. In addition, it is emphasized that the transition from overweight to obesity usually occurs between the ages of 18-29. There are non-formal education programs on obesity management for adolescence and adulthood. It is noteworthy that young people in the university period are not adequately represented in the current education programs, and at the same time, education programs specific to young people are limited. The aim of this study is to determine the effects of technology-based motivation education prepared according to the health belief model on obesity-related beliefs and attitudes, nutrition-exercise behaviors, self-efficacy and weight management in obese university students. This quasi-experimental pretest-posttest randomized controlled study will be carried out at Sivas Cumhuriyet University Suşehri Health College and Suşehri Timur Karabal Vocational School between February 1, 2022 and September 15, 2022. The sample of the study will consist of 84 students (experimental group n= 42 and control group n=42). A web-based technology based motivation program including motivational interviewing will be applied to the students in the experimental group. The control group will only receive web-based education on obesity. Data will be collected using Personal Information Form, Obesity Health Belief Model Scale, Nutrition-Exercise Behavior Scale, Self-Efficacy-Efficacy Scale and Website Usability Scale. physical measurements; A digital height-weight meter will be used for BMI measurement, and a tape measure will be used for waist and hip circumference. Whether the data is normal or not will be determined by Kolmogorov-Smirnov, Shapiro Wilk tests. In order to determine whether there is a difference in the research, necessary parametric and nonparametric tests will be used depending on whether the assumptions are met or any or all of the assumptions are not met.
Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high-resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. Immunoglobulin A-positive (IgA+) PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia.
Biliary tract disorders including cholelithiasis, cholecystitis, and other diseases of the biliary tract, are one of the most prevalent medical issues in the digestive system, posing a myriad of challenges for health workers and patients. Gallbladder dysfunction is the most frequent cause of symptomatic and complicated biliary tract disorders. Although gallbladder dysfunction is a common condition in Middle East countries, data on the incidence of end-stage renal disease (ESRD) are limited. The occurrence of gallbladder dysfunction in patients fed with low-protein diets suggests that gallbladder stones formation is affected by dietary protein content. Also the lithogenic composition changes of bile, increased nucleation tendency, and impaired motility of gallbladder are important factors in ESRD patients. It has been reported that chronic kidney disease (CKD) patients on regular hemodialysis (HD) have increased bile cholesterol levels and an increased bile saturation index. In addition, the gallbladder is innervated by the autonomic nervous system, which malfunctions in uremia, and it has been shown that gallbladder stasis might cause increased stone formation. In some studies, the prevalence of gallbladder dysfunction has been shown to increase in patients undergoing hemodialysis (HD) treatment for ESRD. So, we focused in this study to try to find association of gallbladder dysfunction in pre-dialysis ESRD and HD patient in comparison to normal renal function individuals.
PURPOSE: A composition containing Liriope platyphylla extract, fraction thereof, or compounds isolated from the same is provided to effectively prevent or treat inflammatory diseases. CONSTITUTION: A composition with anti-inflammatory function contains Liriope platyphylla extract, fraction thereof, or compounds isolated from the same as an active ingredient. The extract is prepared using water, low carbon number alcohol, and mixture solvent thereof. The low carbon number alcohol is hexane or ethyl acetate. The compound is hydroxypropyl cellulose. A pharmaceutical composition for preventing and treating inflammation contains the extract, fraction, or compound as an active ingredient.
Hearing loss constitutes one of the most prevalent conditions within the field of otolaryngology. Recent investigations have revealed that mutations in deafness-associated genes, including point mutations and variations in DNA sequences, can cause hearing impairments. With the ethology of deafness remaining unclear for a substantial portion of the affected population, further screenings for pathogenic mutations are imperative to unveil the underlying mechanisms. On this study, by using next-generation sequencing, we examine 129 commonly implicated deafness-related genes in a Chinese family with hearing loss, revealing a novel heterozygous dominant mutation in the GJB2 gene (GJB2: c.65T>G: p. Lys22Thr). This mutation consistently occurs in affected family members but is not detected in unaffected individuals, strongly suggesting its causative role in hearing loss. Structural analysis indicates potential disruption to the Cx26 gap junction channel's hydrogen bond and electrostatic interactions, aligning with predictions from the PolyPhen and SIFT algorithms. In conclusion, our study provides conclusive evidence that the identified heterozygous GJB2 mutation (GJB2: c.65T>G: p. Lys22Thr), specifically the K22T alteration, is the primary determinant of the family's deafness. This contribution enhances our understanding of the interplay between common deafness-associated genes and hearing loss, offering valuable insights for diagnostic guidance and the formulation of therapeutic strategies for this condition.
OBJECTIVES: The population attributable fraction (PAF), an epidemiologic measure of exposures and health outcomes, can provide information on the public health impacts of exposures in populations. This study aimed to systematically summarize the PAF estimates of modifiable cancer risk factors in Korea.
METHODS: This review included studies that determined PAFs of modifiable risk factors for cancer in Korea. We performed systematic searches in EMBASE, MEDLINE, Cochrane library, and Korean databases for studies published up to July 2021. Two reviewers independently screened studies for eligibility, extracted data, and performed quality assessments of the included studies. Due to high variability among the data acquisition methods and PAF estimates, we presented the results qualitatively and did not perform quantitative data synthesis.
RESULTS: We reviewed 16 studies that reported the PAFs of risk factors for cancer, including smoking, alcohol consumption, obesity, and various cancer sites. We found considerable variability in the PAF estimates across exposure and cancer pairs. However, PAF estimates for smoking and respiratory cancer were consistently high in men. PAF estimates were higher in men than in women for smoking and alcohol consumption but higher in women for obesity. We found limited evidence for other exposures and cancers.
CONCLUSION: Our findings may be used to prioritize and plan strategies to reduce cancer burden. We encourage further and updated assessments of cancer risk factors, including those not addressed in the studies included in this review, and their potential contributions to cancer burden to better inform strategies for cancer control.
Hepatotoxicity with allergic features including life-threatening events has been reported in clinical trials and postmarketing. Severe rash or evidence of systemic allergic reaction including drug-related rash with fever, eosinophilia, elevated IgE, or other systemic symptoms have been reported in conjunction with hepatotoxicity [ see Warnings and Precautions ( 5.2) ]. These events occurred approximately 1 month after starting treatment. Among reported cases of hepatitis, some were observed in the absence of allergic features or with no pre-existing hepatic disease. 

Appropriate laboratory testing including ALT, AST, and bilirubin should be conducted prior to initiating therapy with maraviroc and at other time points during treatment as clinically indicated. Hepatic laboratory parameters should be obtained in any patient who develops rash, or signs or symptoms of hepatitis, or allergic reaction. Discontinuation of maraviroc should be considered in any patient with signs or symptoms of hepatitis, or with increased liver transaminases combined with rash or other systemic symptoms.   
  
When administering maraviroc to patients with pre-existing liver dysfunction or who are co-infected with hepatitis B and/or C virus, additional monitoring may be warranted. The safety and efficacy of maraviroc have not been specifically studied in patients with significant underlying liver disorders.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: invention relates to development of agent of plant origin showing hypolipidemic and antioxidant effects. Agent is made as syrup containing plantain leaves extract, refined sugar, correcting agents as aromatic principles and purified water. Agent does not induce hypoxic symptoms and can be used as curative-prophylactic agent in corresponding doses. EFFECT: enhanced effectiveness of agent. 1 cl, 1 ex
A pharmaceutical colloidal composition comprises a mixture of hyaluronic acid biopolymers having different specific molecular weights mixed in a determined ratio. The mixture is dispersed in a diluent selected from distilled water, saline, dimethylsulfoxide or an alcohol solution. ACTIVITY : Respiratory Gen.; Antiasthmatic. A 4.5% hyaluronic acid colloidal composition contained demineralized water (950 g), hyaluronic acid mixture (45 g) and methyl parabenzoate (5 g). The composition in an aerosol form was tested on asthmatic patients. The aerosol composition was administered 30 minutes prior to patient exposure to non specific challenges. It was found that the composition was effective in the treatment of asthma, with nondetectable differences between patients with different forms of asthma. MECHANISM OF ACTION : None given.
For 8 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calories-containing beverages within an 8 to 10-hour period that fits their schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day).
Sudden hemorrhage stemming from internal organ wounds poses a grave and potentially fatal risk if left untreated. Injectable-hydrogel-based tissue sealants featuring multiple actions, including fit-to-shape in situ gelation, rapid hemostasis, pro-angiogenic, anti-bacterial and outcome tracking, are ideal for the management of organ trauma wounds. Herein, an injectable-hydrogel tissue sealant AN@CD-PEG&TQ which consists of four-arm 4-arm poly(ethylene glycol) (PEG-SC) succinimidyl carbonate), AN@CD nanoprobe, and two bioactive peptides (anti-microbial peptide Tet213 and pro-angiogenic peptide QK) is developed. Among them, AN@CD nanoparticles form through host/guest complexation of amino-group-containing β-cyclodextrin and adamantyl group, enabling in situ biomarker (NO)-activatable optoacoustic/NIR-II: Near-infrared second biological window fluorescent imaging. The ample ─NH2 groups on the surface of AN@CD readily engage in rapid cross-linking with succinimidyl ester groups located at the ends of four-arm PEG-SC. This cross-linking expedites the gelation process without necessitating additional initiators or cross-linking agents; thus, significantly enhancing both hydrogel's application convenience and biocompatibility. Bioactive peptides (Tet213 and QK) safeguard against possible bacterial infections, facilitate angiogenesis, and eventually, improve organ wounds healing. This hydrogel-based tissue sealant demonstrates superior therapeutic and bioimaging performance in various mouse models including liver hemorrhage, gastric perforation, and bacterial-infected skin wound mouse models, highlighting its potential as a high-performance wound sealant for organ bleeding wound management.
The invention discloses a novel method used for preparing general flavones from the root of Lauraceae Lindera plant Lindera reflexa Hemsl.. The novel method comprises following steps: Lindera reflexa Hemsl. is extracted with ethanol, an obtained extract is recycled and concentrated, and is dispersed in water; impurities are absorbed using a macroporous resin column; solvents are recycled, and an obtained product is delivered through a macroporous resin column again; ethanol or methanol is used for elution; an obtained eluent is subjected to decolouring with active carbon, and then is concentrated and dried so as to obtain the Lindera reflexa Hemsl. general flavones. Technology of the novel method is simple; cost is low; no pollution is caused; the novel method is advanced and safe, and possesses excellent applicability; the extracted Lindera reflexa Hemsl. general flavones can be used for preparing drugs used for treating gastric ulcer and analgesic anti-inflammatory drugs; phamaceutical value of Lindera reflexa Hemsl. is increased; and the novel method is an innovation in the field of drugs.
In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
The PASTrial is a non-commercial, multi-center, randomized, placebo-controlled, double blinded clinical trial. The study compares dexmedetomidine versus normal saline (placebo) in patients after intracranial surgery with delayed extubation. In dexmedetomidine group, infusion (0.4μg/kg/h) is started when patients are admitted to neuro-intensive care unit for postoperative recovery. In control group, patients receive normal saline infusion at the same rate and volume in dexmedetomidine group. The patient's level of sedation is assessed by Sedation-Agitation Scale (SAS) per hour. Midazolam is administered in 0.3-0.5 mg bolus or continuous infusion as SAS above 4. The study is designed primarily to compare the percentage of patients with agitation and requiring midazolam infusion in the 2 study arms.
PURPOSE: To obtain a nutritionally perfect co-randomized fat compsn. for an infant consisting of specified amts. of lauric acid, palmitic acid, oleic acid and linolic acid type oils and contg. the palmitic acid and lauric acid type oils in a co-randomization state. CONSTITUTION: This co-randomized fat compsn. consists of 18-30wt.% lauric acid type oil consisting of coconut oil, babasu oil and/or palm kernel oil, 20-40wt.% palmitic acid type oil consisting of oleo oil, palm oil and/or palm olein oil, 13-34wt.% oleic acid type oil consisting of olive oil, safflower oleic acid oil, sunflower oleic acid oil and/or canola oil and 12-27wt.% linolic acid type oil such as corn oil, cotton seed oil or safflower oil and contains the palmitic acid and lauric acid type oils in a co-randomized state.
An increased risk of congenital malformations associated with theuse of minor tranquilizers (meprobamate, chlordiazepoxide anddiazepam) during the first trimester of pregnancy has beensuggested in several studies. Because use of these drugs is rarelya matter of urgency, their use during this period should almostalways be avoided. The possibility that a woman of childbearingpotential may be pregnant at the time of institution of therapyshould be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant theyshould communicate with their physician about the desirability ofdiscontinuing the drug.

Meprobamate passes the placental barrier. It is present both inumbilical cord blood at or near maternal plasma levels and inbreast milk of lactating mothers at concentrations two to four timesthat of maternal plasma. When use of meprobamate iscontemplated in breastfeeding patients, the drug's higherconcentration in breast milk as compared to maternal plasmashould be considered.
A prolonged acting zinc insulin preparation comprises an aqueous suspension of crystalline or amorphous zinc insulin or a mixture thereof, which may contain at least 1.5 per cent by by weight of chemically bound zinc, in a succinate buffer which may be of pH 6 to 7.5.  Crystalline zinc insulin containing about 0.45 to 0.9 per cent by weight of zinc may be prepared according to U.S.A.  Specifications 2,143,590 and 2,626,228 or by dissolving zinc insulin in an aqueous mixture of glacial acetic acid and zinc acetate, adjusting the pH to between 5.9 and 6.0 by addition of ammonium hydroxide and separating the precipitated zinc insulin. The preparation may be prepared by mixing a solution containing zinc insulin, zinc chloride and sufficient hydrochloric acid to provide a pH of 2.8 to 3.2, with an alkaline solution of succinic acid and sufficient sodium hydroxide to provide a final pH of the mixture of 6 to 7.5, the mixture having a total zinc concentration including zinc derived from the zinc insulin of substantially 2 mg/1000 units of insulin.  The preparation may also contain phenol and glycerine.  Belgian Specification 502,327 is referred to.
BACKGROUND: Kidney transplantation is the best mode of kidney replacement therapy. However, the shortage of organ donations has been a major challenge globally. Relatives of patients with end-stage kidney disease (ESKD) are potential kidney donors. We explored their perspectives about kidney donation, kidney commercialisation, and barriers to kidney donation.
METHODS: In-depth interviews were conducted among 28 relatives of ESKD patients across the six geopolitical zones and Federal Capital Territory of Nigeria. The interview focused on potential sources of kidney donors, kidney commercialisation and barriers to kidney donation. ATLAS.ti version 9.0.22.0 was used for data analysis.
RESULTS: Mean age of the study participants was 41.57 ± 14.55 years; 54% were females, 60.7% were married, 93% had tertiary education and 75% were first degree relatives of ESKD patients. There were 7 themes and 28 subthemes generated in this study. The potential sources of kidney donors identified by the study participants included commercial, hospital, family and non-family member donors. While some opined that a family member is the best choice as a kidney donor, others preferred a commercial donor. The majority of those interviewed do not believe that it is wrong to purchase a kidney, and would be willing to do so. Identified factors that promote kidney commercialisation were unwillingness of a family member to donate, having the financial capacity to purchase a kidney, non-fitness of family members to donate. Identified barriers to kidney donation were age, poor health status, polygamy, perceived poor expertise of the medical team, perceived risk of the procedure, parental influence and religious beliefs.
CONCLUSIONS: The majority of participants lacked correct information about kidney donation. Implementation of educational program policies and laws regulating and reinforcing ethical principles of kidney donation and transplantation should be ensured.
Premenopausal women: Baseline blood and genital samples will be taken in the follicular and luteal phase (visits 2 and 3). The participant will be given TFV gel and instructed to insert two doses, separated by 2 hours, and return to the clinic 3 hours after the second insertion for blood and genital samples (visits 4/4a and 5/5a).

Postmenopausal women: Premenopausal women: Baseline blood and genital samples will be taken (visit 2). The participant will be given TFV gel and instructed to insert two doses, separated by 2 hours, and return to the clinic 3 hours after the second insertion for blood and genital samples (visit 3/3a). Estradiol cream will be distributed at visit 4. Post estradiol blood and genital samples will be taken at Visit 5. The participant will given TFV gel and instructed to insert 2 doses as before, while continuing to use the estradiol cream. Post TFV gel and estradiol cream blood and genital samples will be taken (visit 6/6a).
PURPOSE:To obtain a tooth surface cleaning agent, composed of a suspension prepared by dispersing a powdery cation exchange resin in water, capable of cleaning a smear layer formed on the enamel, etc., due to cutting, etc., by applying to the tooth surface and excellent in adhesion to a dental reparative material without any irritancy. CONSTITUTION:A suspension is obtained by dispersing a powdery cation exchange resin in water. The cation exchange resin is preferably a polystyrene- based gel type strong acidic cation exchange resin, a phenolic strong acidic cation exchange resin, etc. The aforementioned exchange resin is used in a powdery form and the particle diameter thereof is preferably 150 mesh or below. Although the above-mentioned powder is dispersed in water to provide the suspension, the dispersion concentration is preferably >=1%. In clinical use, the aforementioned agent is applied to enamel or dentin surfaces, etc., brought into contact with tooth surfaces for >=10sec, preferably >=30sec and then removed by washing with water.